AlphaMadera's AlphaVal page classifies USANA Health Sciences, Inc. as a Stable Earnings Power business and values it using P/Adj-EPS × Normalized Multiple, then compares the result to the current market price to flag USNA as undervalued, fairly valued, or overvalued.

What is USANA Health Sciences, Inc.'s fair value?

Fair value for USNA comes from a P/Adj-EPS × Normalized Multiple model -- the approach AlphaVal selected for this company's Stable Earnings Power classification. The live AlphaVal page shows bear, base, and bull scenarios alongside the key assumption behind each.

How does AlphaMadera value USNA?

AlphaVal routes each company to one of ten valuation archetypes based on its business model. USNA was classified as Stable Earnings Power and is valued using P/Adj-EPS × Normalized Multiple, built from USNA's most recent reported fundamentals.

USNA - USANA Health Sciences, Inc.

Price: -- -- | CONSENSUS: Hold DETAILS | PRICE TARGET: $35.00 DETAILS

AlphaVal

Deterministic, archetype-aware fair value

Stable Earnings Power 80% confidence

Primary model: P/Adj-EPS × Normalized Multiple

Valuation Signal Undervalued Strong

Trading 79.1% below fair value

Current Price $13.67

Bear Case $53.82 293.7% upside ($53.82 - $13.67) / $13.67 = 293.7% $3.84 × 14x P/E

Fair Value $65.35 378.0% upside ($65.35 - $13.67) / $13.67 = 378.0% $3.84 × 17x P/E

Bull Case $76.88 462.4% upside ($76.88 - $13.67) / $13.67 = 462.4% $3.84 × 20x P/E

Adjust Assumptions

P/E Multiple

17.0x

Adjusted EPS

3.84$

Key Value Driver

Normalized P/E multiple (17x base case)

Terminal Value % of EV

Implied Market Multiple 3.6x

Market is pricing in (growth)

Plain-Language Summary

Applying a 17x P/E to adjusted EPS of $3.84, the base-case value is $65.35 per share.

Analyst Consensus (External Reference)

Never blended into the bear/base/bull estimates above -- shown only as an outside comparison.

Average Target (8 analysts) $35.00

Analyst Range $35.00 – $35.00

Divergence from AlphaVal 87%

Warnings

⚠ The company's reported profits differ from official accounting profits by 563%. Check what costs are being left out of the adjusted number.

ℹ Wall Street's average price target is $35.00 (from 8 analysts). Our estimate is 87% above the consensus -- consider that gap carefully.

⚠ This stock is 58% below its 52-week high, with weak or declining earnings. That combination often signals real trouble, even though the valuation below is based on other fundamentals.

Key Risks

Growth DCF inappropriate — terminal value assumptions dominate
EV/EBITDA misleading for regulated businesses where capex is mandated
Regulatory risk is a fat tail not visible in normal multiples